Cartesian Therapeutics has a strong cash position after a $130 million equity raise, extending its runway to support upcoming ...
Analyst Thomas Smith of Leerink Partners maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), retaining the price ...
DNA (pDNA) purification system. PlasmidPro enables innovation at scale, providing complete automation across mini and maxi ...
WestGene Biopharma, a leading innovator in mRNA therapeutics, presented the latest clinical data for its EBV-positive tumour ...
NTx’s new services offering provides faster and more affordable high-integrity, complex mRNA production powered by NTxscribe® ...
News Medical on MSN6d
Early data shows mRNA-4359 may benefit patients with advanced solid cancersInterim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients ...
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients ...
4don MSN
Jim Cramer’s 10 Best Stock Picks for Investors Right Now. In this article, we are going to take a look at where Moderna, Inc.
CAMBRIDGE, Mass. - Omega Therapeutics, Inc. (NASDAQ:OMGA) has announced promising preclinical results for its novel epigenomic mRNA therapy, OTX-2002, in models of hepatocellular carcinoma (HCC ...
CAMBRIDGE, Mass. - Omega Therapeutics, Inc. (NASDAQ:OMGA) has announced promising preclinical results for its novel epigenomic mRNA therapy, OTX-2002, in models of hepatocellular carcinoma (HCC), the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback